Quarterly ResultMay 15, 2026, 04:19 PM
Lantern Pharma Q1 Net Loss Reduced 27%; Launches withZeta.ai & Plans Spin-off
AI Summary
Lantern Pharma reported a 27% year-over-year reduction in net loss for Q1 2026, reaching approximately $3.3 million, alongside a 47% decrease in R&D expenses. The company commercially launched withZeta.ai, its multi-agentic AI co-scientist platform, and announced a strategic plan to create an independent entity for these AI assets. Additionally, Lantern Pharma achieved significant clinical milestones, including FDA IND clearance for its subsidiary Starlight Therapeutics' pediatric CNS cancer trial and a successful FDA Type C meeting for the LP-300 HARMONIC Clinical Trial. The company's pro forma liquidity is expected to fund operations into the middle of the first quarter of 2027.
Key Highlights
- Q1 2026 net loss reduced 27% year-over-year to approximately $3.3 million ($0.30 per share).
- Research and development expenses decreased 47% year-over-year to approximately $1.7 million.
- Cash, cash equivalents, and marketable securities were approximately $6.3 million as of March 31, 2026.
- Pro forma liquidity, including $4.4 million from May 14, 2026 financing, funds operations into Q1 2027.
- Commercial introduction of withZeta.ai, a multi-agentic AI co-scientist platform.
- FDA IND cleared for Starlight Therapeutics' pediatric brain cancer trial (STAR-001).
- Successful outcome from FDA Type C meeting for LP-300 HARMONIC Clinical Trial.
- Strategic plan to create an independent entity for withZeta.ai assets announced.
Price Impact
More from LTRN